Summary
The European Parliament opposes the authorization of GM soybean MON 87751 due to scientific concerns about allergenicity and flaws in toxicity testing, while also criticizing the lack of democratic legitimacy in the decision-making process. 10 27.03.2019
Other
health
environment
agriculture, forestry and fisheries
Key points
- The motion opposes the authorization of genetically modified soybean MON 87751 for food and feed use.
- There are concerns that Bt toxins may act as adjuvants, potentially increasing the allergenic properties of other foods.
- Existing toxicity studies are criticized for not simulating real-world exposure and for failing to meet all OECD requirements.
- The 90-day feeding studies are identified as having weaknesses, including insufficient dosage variety and lack of contamination analysis.
Documents (PDFs)
MOTION FOR A RESOLUTION on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87751 (MON-87751-7), pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council
Genetically modified soybean MON 87751 (MON-87751-7)
These raw data are provided by the Open Data Portal of the European Union (data.europa.eu) and are licensed under ODC-BY 1.0.